Geometric Design

Release Details

Semler Scientific, Inc. harvest heart image

Semler Scientific to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 5, 2023

SANTA CLARA, Calif., April 5, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Wayne T. Pan, Ph.D., M.D., and head of corporate communications and business strategy, Renae Cormier, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 4:30 pm ET. Management will also participate in one-on-one calls with investors on Tuesday, April 18.

A live webcast will be available under "Events and Presentations" on the "Investor Info" section of Semler Scientific's website and may be accessed through the following link: The presentation will be archived for a period of 90 days after the conference.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific's patented and U.S. Food and Drug Administration (FDA), cleared product, QuantaFlo, is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of mortality and major adverse cardiovascular events (MACE), which are associated with a positive QuantaFlo test. Semler Scientific has an agreement with Mellitus Health, Inc. (Mellitus) to exclusively market and distribute Insulin Insights™, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico, except for selected accounts. Semler Scientific has made investments in Mellitus, NeuroDiagnostics Inc., a privately held company doing business as SYNAPS Dx, whose product, Discern™, is a test for early stage Alzheimer's disease, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool™ offers a technology-enabled approach to inpatient glycemic management. Semler Scientific continues to develop complementary innovative products in-house, and seek out other arrangements for additional products and services that it believes will bring value to its customers and to the company. Semler Scientific believes its current products and services, and any future products or services that it may offer, positions it to provide valuable information to its customer base, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at

Susan A. Noonan
S.A. Noonan Communications
917 513 5303



View original content to download multimedia:

SOURCE Semler Scientific, Inc.

Email alerts background images